Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis

40Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Heart failure is the usual cause of death in patients with amyloid cardiomyopathy. The commonest form of hereditary cardiac amyloidosis is associated with the Val122Ile variant of transthyretin (TTR), which is carried by 3-4% of the African American population. Here, we report the outcome of the first cardiac transplantation in a patient with TTR V122I. A 59-year-old Caribbean man presented with biventricular failure. Other than previous bilateral carpel tunnel syndrome, he had been well and had no evidence of extracardiac amyloidosis. An endomyocardial biopsy demonstrated amyloid of TTR type. Sequencing of TTR gene indicated homozygosity for V122I. He underwent cardiac transplantation and 3 years later, remains well with no evidence of allograft or systemic amyloid deposition. © 2008 The Authors.

Cite

CITATION STYLE

APA

Hamour, I. M., Lachmann, H. J., Goodman, H. J. B., Petrou, M., Burke, M. M., Hawkins, P. N., & Banner, N. R. (2008). Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. American Journal of Transplantation, 8(5), 1056–1059. https://doi.org/10.1111/j.1600-6143.2008.02162.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free